



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 17:40
Last Report Issued 09/07/2011 07:13

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2501SP
Patient ID 2501SP
Chain 11001777
DOB Not Given
Sex Not Given
Workorder 11001777
Received 09/07/2011

Lab ID 11001777-001
Matrix Serum or Plasma
Patient Name 2501SP
Patient ID 2501SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2501SP Levamisole, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Levamisole	None Detected	mcg/mL	0.10	
Synonym(s): Levasole®; Ergamisol®				

Levamisole is used as a veterinary antihelminthic (worming agent) in animals. It is no longer available in North America for human use. However, from July-September 2008 approximately 30% of cocaine seized by the DEA was contaminated with levamisole. There is limited data available on therapeutic concentrations of levamisole and no data on levamisole concentrations encountered from tainted cocaine. The mean peak plasma concentration following a single 2.5 mg/kg dose was 0.48 +/- 0.22 mcg/mL. Following a single 50 mg dose the mean peak plasma concentration was 0.13 mcg/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.